RASONQUE Wins Breakthrough Status for First-Line Use

Q: What data supports the designation?

Data from RMC-GI-102, an open-label, multicenter Phase 1/2 trial, in treatment-naive patients with RAS-mutant metastatic PDAC who received RASONQUE plus gemcitabine and nab-paclitaxel. Revolution Medicines said the combination showed encouraging preliminary antitumor activity and a manageable safety profile. Those results informed the design of RASolute 303, the ongoing global Phase 3 trial testing RASONQUE as monotherapy and in combination with GnP against GnP alone in previously untreated metastatic PDAC.

Q: How many Breakthrough Therapy designations does RASONQUE now have?

This is RASONQUE's third Breakthrough Therapy designation and the fifth across Revolution Medicines' RAS(ON) inhibitor portfolio, according to the company. The drug's second-line monotherapy use was itself approved under an expedited pathway, via a national priority voucher, roughly a month after FDA accepted the application.

Three weeks after its second-line approval, Revolution Medicines' RAS inhibitor daraxonrasib — marketed as RASONQUE — has picked up a third Breakthrough Therapy designation, this time for a front-line use. FDA granted the designation September 14, 2026, for RASONQUE combined with gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, based on early-phase data that is now feeding an ongoing Phase 3 trial against the current chemotherapy standard of care.

In brief

FDA granted the designation September 14, 2026, for RASONQUE plus gemcitabine and nab-paclitaxel in treatment-naive metastatic pancreatic ductal adenocarcinoma — a first-line, not second-line, use.
The basis: Phase 1/2 trial RMC-GI-102, an open-label study showing “encouraging preliminary antitumor activity and a manageable safety profile” in treatment-naive, RAS-mutant patients.
That data now informs the design of RASolute 303, the ongoing global Phase 3 trial testing RASONQUE alone and combined with GnP against GnP alone in the first-line setting.
This is RASONQUE's third Breakthrough Therapy designation and the fifth across Revolution Medicines' RAS(ON) portfolio; the drug's second-line monotherapy use was approved August 26, 2026.

A second act for a drug three weeks into its first approval

RASONQUE's second-line approval, which Regulatory News covered on August 26, was itself notable for speed: FDA cleared the drug roughly a month after accepting Revolution Medicines' application, aided by a national priority voucher, on the strength of RASolute 302 — a Phase 3 trial that cut the risk of death by 60 percent against chemotherapy (a hazard ratio of 0.40) and pushed median overall survival to 13.2 months versus 6.7 months, in patients who had already failed at least one prior systemic therapy. That approval addressed a real but narrower population: people whose cancer had already progressed on a first treatment.

The September 14 designation targets a much larger population — patients newly diagnosed with metastatic PDAC who have not yet been treated at all, where gemcitabine plus nab-paclitaxel or a similar multiagent chemotherapy regimen remains the default first move. Moving a targeted RAS inhibitor into that front-line slot, rather than reserving it for later lines of therapy, is the more consequential regulatory and commercial question for the drug class, and it is the one this designation starts to answer.

What the early data actually showed

The designation rests on RMC-GI-102, an open-label, multicenter Phase 1/2 trial that enrolled treatment-naive patients with RAS-mutant metastatic PDAC and treated them with RASONQUE plus the GnP chemotherapy backbone. Revolution Medicines described the results as showing encouraging preliminary antitumor activity alongside a manageable safety profile — the standard early-phase combination of signal and tolerability that Breakthrough Therapy designation is designed to reward with faster, more intensive FDA engagement. Breakthrough status does not itself approve anything; it commits the agency to more frequent meetings, rolling review eligibility, and organizational commitment to an efficient development program, precisely because the underlying data is still incomplete.

The trial that will settle the question

RMC-GI-102's role was to inform, not answer, the first-line question. That job now belongs to RASolute 303, the global Phase 3 trial already underway, which randomizes previously untreated metastatic PDAC patients to RASONQUE monotherapy, RASONQUE plus GnP, or GnP alone. Public trial registry information lists safety and tolerability as the primary endpoints, with objective response rate, disease control rate, and progression-free survival as secondary measures, plus exploratory circulating tumor DNA analyses to track molecular response. A three-arm design against an active chemotherapy comparator is a materially higher bar than the single-arm early-phase work supporting today's designation, and it is the trial sponsors and competitors alike will be watching for a read on whether a RAS inhibitor genuinely displaces chemotherapy as the first-line move rather than following it.

A portfolio built on sequential designations

Revolution Medicines has now collected three Breakthrough Therapy designations for daraxonrasib alone and five across its broader RAS(ON) inhibitor portfolio, a pattern that reflects a deliberate strategy: seek expedited status for each indication and combination as supporting data matures, rather than waiting for one comprehensive filing. For RA/QA teams tracking RAS-pathway competitors, the practical read is that FDA is treating daraxonrasib's front-line combination as a distinct, actively managed development program with its own designation and its own pivotal trial — not a foregone label expansion riding on the second-line approval already secured.

Frequently asked questions

What did FDA grant, and when?

On September 14, 2026, FDA granted Breakthrough Therapy designation to RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel for previously untreated, treatment-naive metastatic pancreatic ductal adenocarcinoma. Revolution Medicines announced the designation the same day.

How is this different from RASONQUE's existing approval?

RASONQUE was approved August 26, 2026, as a monotherapy for patients who had already received prior systemic therapy — second-line or later. This designation covers an investigational first-line combination with chemotherapy that is not yet approved.

What data supports the designation?

Phase 1/2 trial RMC-GI-102, an open-label study in treatment-naive RAS-mutant patients, showing encouraging preliminary antitumor activity and a manageable safety profile. That data informs the ongoing Phase 3 RASolute 303 trial.

How many Breakthrough Therapy designations does RASONQUE now have?

Three for RASONQUE specifically, and five across Revolution Medicines' RAS(ON) inhibitor portfolio, according to the company.

Sources & further reading

Revolution Medicines, “Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer,” September 14, 2026. globenewswire.com
Targeted Oncology, “Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer.” targetedonc.com
OncoDaily, “FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer.” oncodaily.com
FDA, “FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer,” on the August 26, 2026 second-line approval this designation builds on. fda.gov
ClinicalTrials.gov, RASolute 303 (daraxonrasib with or without GnP vs. GnP alone in untreated metastatic PDAC), NCT07491445. clinicaltrials.gov

Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.